Britta Wahren

Britta Wahren

Professor Emeritus/Emerita
Visiting address: Solnavägen 9, C9, 17165 Solna
Postal address: C1 Mikrobiologi, tumör- och cellbiologi, C1 Host-Microbe Arulampalam, 171 77 Stockholm


  • Selected publications:

    Codon optimization and improved delivery/immunization regimen enhance the immune response against wild-type and drug-resistant HIV-1 reverse transcriptase, preserving its Th2-polarity.
    Latanova AA, Petkov S, Kilpelainen A, Jansons J, Latyshev OE, Kuzmenko YV, et al
    Sci Rep 2018 May
  • 8(1):8078

    HIVIS-DNA or HIVISopt-DNA priming followed by CMDR vaccinia-based boosts induce both humoral and cellular murine immune responses to HIV.
    Hinkula J, Petkov S, Ljungberg K, Hallengärd D, Bråve A, Isaguliants M, et al
    Heliyon 2017 Jun
  • 3(6):e00339

    Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous DNA Prime-Modified Vaccinia Virus Ankara Boost HIV-1 Vaccine Regimen.
    Bauer A, Podola L, Mann P, Missanga M, Haule A, Sudi L, et al
    J. Virol. 2017 09
  • 91(18):

    Immunization with HIV-1 envelope T20-encoding DNA vaccines elicits cross-clade neutralizing antibody responses.
    Stenler S, Lundin KE, Hansen L, Petkov S, Mozafari N, Isaguliants M, et al
    Hum Vaccin Immunother 2017 12
  • 13(12):2849-2858

    Three-Year Durability of Immune Responses Induced by HIV-DNA and HIV-Modified Vaccinia Virus Ankara and Effect of a Late HIV-Modified Vaccinia Virus Ankara Boost in Tanzanian Volunteers.
    Joachim A, Munseri PJ, Nilsson C, Bakari M, Aboud S, Lyamuya EF, et al
    AIDS Res. Hum. Retroviruses 2017 08
  • 33(8):880-888

    Early antiretroviral therapy in children perinatally infected with HIV: a unique opportunity to implement immunotherapeutic approaches to prolong viral remission.
    Klein N, Palma P, Luzuriaga K, Pahwa S, Nastouli E, Gibb DM, et al
    Lancet Infect Dis 2015 Sep
  • 15(9):1108-1114

    HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial.
    Nilsson C, Hejdeman B, Godoy-Ramirez K, Tecleab T, Scarlatti G, Bråve A, et al
    PLoS ONE 2015
  • 10(6):e0131748

    Potent functional antibody responses elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults.
    Joachim A, Nilsson C, Aboud S, Bakari M, Lyamuya EF, Robb ML, et al
    PLoS ONE 2015
  • 10(4):e0118486

    Immunotherapy with an HIV-DNA Vaccine in Children and Adults.
    Palma P, Gudmundsdotter L, Finocchi A, Eriksson LE, Mora N, Santilli V, et al
    Vaccines (Basel) 2014 Jul
  • 2(3):563-80

    Broad and potent cellular and humoral immune responses after a second late HIV-modified vaccinia virus ankara vaccination in HIV-DNA-primed and HIV-modified vaccinia virus Ankara-boosted Swedish vaccinees.
    Nilsson C, Godoy-Ramirez K, Hejdeman B, Bråve A, Gudmundsdotter L, Hallengärd D, et al
    AIDS Res. Hum. Retroviruses 2014 Mar
  • 30(3):299-311


All other publications

News from KI

Events from KI